Slides
Page 1
Rapid Micro Biosystems H.C. Wainwright 27th Annual Global Investment Conference Sean Wirtjes, Chief Financial Officer September 9, 2025 R A P I D M I C R O B I O S Y S T E M S N A S D A Q : R P I D © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 2
Rapid Micro Biosystems Disclaimers 2 This presentation has been prepared by Rapid Micro Biosystems, Inc. (the “Company”) solely for informational purposes. This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, expected placements of Growth Direct systems, anticipated timing of such placements and the impact on the Company’s revenue; expectations and goals with respect to continued improvement in gross margins and cash management; and the Company’s Distribution and Collaboration Agreement and the terms thereof, including future collaboration opportunities between the parties. the benefits and features of the Company's products and technology; the Company's goal to achieve cashflow breakeven; the Company's revenue and gross margin expectations, including the drivers thereof; and the Company's efforts to drive sustainable, long-term growth and shareholder value. In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to the Company’s significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the effectiveness of the Company’s sales and marketing efforts; the Company’s ability to sell and place its products with customers; the Company’s ability to develop new products and adapt to technological change; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; competition within the Company’s industry; the Company’s ability to maintain its manufacturing operations; the Company’s efforts to improve gross margins for its products; the Company’s ability to maintain and grow its relationships with its collaborators, including MilliporeSigma; the Company’s ability to manage its collaboration with MilliporeSigma and to realize the intended benefits of the distribution and collaboration agreement; the impact of the terms of the distribution and collaboration agreement on the Company’s business and results of operations; the Company’s ability to negotiate and enter into future collaboration opportunities with MilliporeSigma, and to realize the intended benefits therefrom; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; the impact of macroeconomic volatility on the Company’s business and operations; and the other important factors outlined under the caption “Risk Factors” in the Company’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 12, 2025, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this presentation to reflect changes since the date of this presentation, except as may be required by law. © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 3
Rapid Micro Biosystems C Our vision We are transforming a critical, regulated part of the global pharmaceutical manufacturing process, bringing microbial quality control into the 21st century. The new standard in microbial quality control Rapid Micro Biosystems 3© 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 4
Rapid Micro Biosystems The standard in automating microbial quality control 4 25% Year / Year Growth $28M Total Revenue 2 0 2 4 R E V E N U E G L O B A L S Y S T E M S C U S T O M E R S $15M Recurring Revenue ~150 Cumulative Validations1 ~170 Cumulative Placements1 ~20 Countries1 86% Approved CAR-T Manufacturers 75% Top 20 Global Pharma2 Rapid Micro Biosystems 1 As of June 30, 2025 2 By revenue © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 5
Rapid Micro Biosystems 2022 2023 2024 2025 $17.1M $28.1M $22.5M $32.0M+ Strong and consistent revenue growth and margin improvement 5 +30% R E V E N U E G R O S S M A R G I N 2022 2023 2024 2025 Recurring Non-recurring 50+ percentage point improvement © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc. 1 The Life Science business of Merck KGaA, Darmstadt, Germany, operating in the U.S. as MilliporeSigma 2 2 2 2025 represents guidance as provided on August 12, 2025 Revenue Growth Drivers • New customer wins • Global deployments at existing customers • Merck partnership (distribution) • New products and services • Strong consumable and service growth Gross Margin Expansion Drivers • Reduced product costs • Improving manufacturing efficiency • Merck partnership (supply) • Increasing service productivity • Increasing volume Mid-Term Goal: ~50% GM Exiting 2027 Mid-Term Goal: Revenue CAGR 25% – 30% (2024 – 2027)
Page 6
Rapid Micro Biosystems 6 Distribution & Collaboration Agreement with Merck KGaA1 (MilliporeSigma) Rapid Micro Biosystems © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc. Advances and accelerates top strategic priorities Accelerating Growth Direct system placements Improving gross margins Driving innovation • Global, 5-year, co-exclusive rights to sell Growth Direct systems and consumables. • Minimum commitment for Growth Direct system purchases - first two years. • Access to segments beyond pharma including personal care, medical device, cosmetics and food & beverage. • Collaboration on Supply Agreement to drive efficiencies, reduce product costs and accelerate gross margin improvement. • Collaboration on Joint Product / Technology Innovation. Agreement Highlights 1 The Life Science business of Merck KGaA, Darmstadt, Germany, operating in the U.S. as MilliporeSigma
Page 7
Rapid Micro Biosystems Insecure and lacking data integrity High volume testing and mandated by regulators Manual, paper-based and slow Subjective and prone to human error 7 Challenges in a traditional microbial quality control (MQC) lab © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 8
Rapid Micro Biosystems Scientific and technology innovation Growing demand for more complex therapies Faster & leaner manufacturing Data integrity & security focus Regulatory scrutiny+ F A C T O R S D R I V I N G C H A N G E Discovery & research QC & ANALYSIS Bioprocessing & manufacturing T O D A Y T O D A Y T O D A Y Flexible single use technologiesHigh-throughput R&D automation MQC has not kept up with pharma industry innovation + + + 8Rapid Micro Biosystems © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 9
Rapid Micro Biosystems The Growth Direct® System brings MQC into the 21st Century Discovery & research QC & ANALYSIS Bioprocessing & manufacturing T O D A YT O D A Y T O D A Y 9 Scientific and technology innovation Growing demand for more complex therapies Faster & leaner manufacturing Data integrity & security focus Regulatory scrutiny+ F A C T O R S D R I V I N G C H A N G E + + + © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc. Flexible single use technologiesHigh-throughput R&D automation
Page 10
Rapid Micro Biosystems THE GROWTH DIRECT® (GD) PLATFORM The only fully automated, high-throughput and secure MQC solution… Proprietary Consumables Data & Software Global Validation & Support Services …delivering a compelling value proposition Data Integrity Supports global quality regulatory compliance and improved data handling and management Operational Efficiency Enables faster decision making by accelerating time to results by 50% or faster compared to the traditional method Insight & Accuracy Eliminate human quality control errors, preventing costly recalls and regulatory interventions 10 Introducing the Growth Direct® platform © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 11
Rapid Micro Biosystems Market forces pushing pharma industry to automation 11 Sources: FDA, EvaluatePharma, Alliance for Regen. Medicine © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc. Regulatory Pressure Increasing regulatory scrutiny and enforcement around data integrity and quality Industry Change Growth in complex biologics and cell & gene therapies which require faster, more accurate, higher throughput testing capabilities Large and Growing Market $5B annual recurring revenue + $5B global system opportunity Expanding Manufacturing Capacity Increasing investments in new manufacturing capacity create significant opportunity for automation
Page 12
Rapid Micro Biosystems Growth strategy focused on land and expand augmented by innovation 12 P U R S U E AD J A C E N T M AR K E T S D R I V E E N T E R P R I S E D E P L O Y M E N T S E X P AN D I N T O N E W G E O G R AP H I E S L AU N C H N E W P R O D U C T S AN D S E R V I C E S G R O W N E W C U S T O M E R AD O P T I O N BIO PHARMA (incl. cell & gene) CDMO STERILE INJECTABLE, VACCINE, & OTHER LAND AND EXPAND STRATEGY Sample automation Additional test types (e.g. sterility) Data services, AI and SaaS Automated microbial ID Core Growth Direct Capabilities EM + W/BB + Sterility + EM + W/BB + Sterility + EM + W/BB + Sterility + Site 1 Site 2 Site 3+ © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.
Page 13
Rapid Micro Biosystems 13 C U S T O M E R S E G M E N T S W I T H E S T A B L I S H E D U S E G L O B A L S I T E S W I T H G R O W T H D I R E C T S Y S T E M S of approved CAR-T manufacturers have GD system placed 86% cumulative systems validated ~150 cumulative consumables sold 6.5M+ customer manufacturing sites 100 cumulative systems placed ~170 of top 20 global pharma are customers 75% G R O W T H D I R E C T AP P L I C AT I ON S Environmental Monitoring Water Testing Bioburden Testing Rapid Sterility Testing Rapid Micro Biosystems Biologics Small Molecules CDMO Personal Care Products Cell & Gene Therapy / CAR-T Customer base includes 75% of the top 20 global pharma companies1 with significant growth potential © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc. 1 By revenue
Page 14
Rapid Micro Biosystems 14 Growth Direct® is the industry-leading platform Chosen by 75% of the top 20 global pharma companies1 with significant commercial runway Operating behind strong barriers to entry First mover advantage, little competition & robust patent portfolio Enabling advanced pharmaceutical manufacturing Growth Direct systems placed with 86% of approved CAR-T manufacturers An expanding $10B+ market Dominated by manual, legacy processes that face increasing FDA scrutiny Attractive, high-growth business model Driving high-yield recurring revenue Rapid Micro Biosystems Creating the future of rapid, secure MQC automation to drive sustainable, long-term growth and shareholder value 1 By revenue © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc. 14
Page 15
Rapid Micro Biosystems Thank you © 2025, Rapid Micro Biosystems, Inc. | RAPID MICRO BIOSYSTEMS® and GROWTH DIRECT® are registered trademarks of Rapid Micro Biosystems, Inc., and the company logo is a trademark of Rapid Micro Biosystems, Inc.